Kubesova B, et al. – An analysis was set up to detect low–burden TP53 mutations in the chronic phase of myeloproliferative neoplasm (MPN). The strongest factor affecting low–burden TP53 mutation incidence in MPN was patient's age. In addition, no significant age–independent association was noticed between TP53 mutations and hydroxyurea. This study suggested the persistence of mutations at low levels for years without an immediate risk of progression.